FORT LAUDERDALE, Fla., April 28, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its first quarter financial results on Thursday, May 12, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
| Conference Call and Webcast | ||
| Date and Time: | Thursday, May 12, 2022 at 4:30 p.m. ET | |
| Domestic: | 844-825-9789 | |
| International: | 412-317-5180 | |
| Passcode: | 10166381 | |
| Webcast: | https://event.choruscall.com/mediaframe/webcast.html?webcastid=yaYf8LWA | |
A replay of the webcast will be archived on the Motus GI website, www.motusgi.com, for 90 days following the event.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Investor Contact:
Troy Williams
LifeSci Advisors
(518) 221-0106
twilliams@lifesciadvisors.com
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…